# Alkion BioInnovations

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alkion-bioinnovations

- Industry: Biotechnology
- Headquarters: Versailles, France
- Website: www.alkinnov.com
- Total disclosed funding: $1.6M
- Latest round: Seed (Oct 28, 2025)
- Investors on record: 2

## About

Based in France, Alkion BioInnovations specializes in bioproduction technologies, focusing on sustainable methods for generating high-value active ingredients for the pharmaceutical sector, particularly in vaccine development.Founded in 2017 in Versailles, France, Alkion BioInnovations operates in the bioproduction sector, specializing in high-value active ingredients. The company has undergone strategic pivots to enhance its operations. In November 2025, Alkion raised EUR 4.4 million in a Seed funding round led by GO Capital, with participation from Critical Path Ventures, bringing its total amount raised to EUR 4.4 million. As of now, the company has executed one notable deal in its operational history.Alkion BioInnovations specializes in the bioproduction of high-value active ingredients, primarily targeting the pharmaceutical sector for vaccine and treatment development. Their core offerings revolve around advanced plant tissue technologies, including a patented process for biostimulation of plant genes in bioreactors, resulting in yields up to 800 times greater than traditional greenhouse methods. Their sustainable products utilize closed-circuit technology to minimize carbon footprint, water usage, and waste, serving pharmaceutical companies and research organizations in Europe, North America, and parts of Asia.Alkion BioInnovations generates revenue through strategic partnerships and collaborations with pharmaceutical companies and research institutions, focusing on the development and supply of active compounds for vaccine production. They may engage in direct B2B transactions where clients contract for specific bioproduction services or utilize proprietary technologies like the Alkaburst 2.0 production system. These transaction structures typically involve multi-year agreements detailing production capacity, pricing, and delivery timelines, positioning their offerings as premium due to high yield and sustainability.Alkion BioInnovations plans to utilize the EUR 4.4 million raised in Seed funding to expand its bioreactor capacity, improve purification processes, and advance its plant-based vaccine-adjuvant programs. The company aims to design and launch new products, enhancing its market presence. There are also intentions to expand into new geographic regions, specifically targeting emerging markets in Asia and North America by 2026. The funding will be instrumental in supporting these growth initiatives.

## Funding rounds

- Seed, Oct 28, 2025, $1.6M — Go Capital, Critical Path Ventures

## Investors

- Go Capital — Seed
- Critical Path Ventures (https://capitalatlas.ai/funds/critical-path-ventures) — Seed